Imfinzi Improves Survival Outcomes in Subgroups of Patients with …
WEB9 hours ago · The 36-month OS rates were 62.1% versus 56.5%, respectively. Among patients who had no prior PCI in the Imfinzi (122 patients) and placebo (123 patients) groups, data showed a median OS of 37.3 months and 24.1 months in each group. After three years, the OS rates were 50.2% with Imfinzi versus 37.3% with placebo.
Imfinzi is first and only immunotherapy to show survival benefit in ...
WEBJun 2, 2024 · Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiation therapy.
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in
WEBJun 25, 2024 · Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiation therapy.
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
WEBJun 25, 2024 · The immunotherapy drug durvalumab (Imfinzi) helped people with early-stage small cell lung cancer live longer, according to initial results from a large clinical trial. Durvalumab is a type of immunotherapy called an immune checkpoint inhibitor.
IMFINZI® (durvalumab) is the first and only immunotherapy to …
WEBJun 2, 2024 · IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo...
FDA expands approval of Imfinzi to reduce the risk of non-small …
WEBThe U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 …
WEB5 days ago · AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Published Sep 19, 2024 8:00am EDT
AstraZeneca immunotherapy extends survival by two years in rarer …
WEBJun 2, 2024 · AstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live 23 months longer than those who received just chemoradiotherapy, according to clinical trial data released Sunday.
IMFINZI plus chemotherapy tripled patient survival at three years …
WEBSep 18, 2021 · IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer. Longest survival follow-up ever reported for immunotherapy treatment in this setting. Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with a ...
Imfinzi significantly improved overall survival and progression-free ...
WEBApr 5, 2024 · Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial. PUBLISHED 5 April 2024. First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial. Positive high-level results of the ADRIATIC Phase III ...
- Some results have been removed